P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 592-596

  Schepers, Eva ^a   Meert, Natalie ^a   Glorieux, Griet ^a   Goeman, Jan ^b   Van der Eycken, Johan ^b   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Immune response; Leucocytes; Oxidative burst activity; Uraemic toxins; Vascular disease

Indexed keywords

CRESOL; FREE RADICAL; PARA CRESYLSULFATE; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; UREMIA; VASCULAR DISEASE;

BIOLOGICAL MARKERS; CRESOLS; ENDOTOXINS; ESCHERICHIA COLI; FREE RADICALS; HUMANS; LEUKOCYTES; RESPIRATORY BURST; SULFURIC ACID ESTERS; UREMIA;

EID: 33846659447     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl584     Document Type: Article

References (29)

1. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999; 10: 1815-1823
2. Vanholder R, Argiles A, Baurmeister U et al. Uremic toxicity: Present state of the art. Int J Artif Organs 2001; 24: 695-725
3. Vanholder R, Massy Z, Argiles, A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
4. Ross R. Atheroscierosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
5. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif 2001; 19: 143-151
6. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001; 19: 53-61
7. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993; 3: 1541-1554
8. Vanholder RC, Ringoir SM. Adequacy of dialysis: A critical analysis. Kidney Int 1992; 42: 540-558
9. Vanholder R, De Smet R, Waterloos MA et al. Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517
10. Wratten ML, Tetta C, De Smet R et al. Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 1999; 17: 134-141
11. Dou L, Cerini C, Brunet P et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009
12. De Smet R, Van Kaer J, Van Vlem B, Lameire N, Vanholder R. The toxicity of the free non-protein bound fraction of P-cresol: A prospective and cross-sectional analysis. J Am Soc Nephrol 2002; 13: 590A
13. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243
14. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
15. Curtius HC, Mettler M, Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580
16. Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997; 105 [Suppl 4]: 739-747
17. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538
18. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436
19. Feigenbaum J, Neuberg CA. Simplified method for the preparation of aromatic sulfuric acid esters. J Am Chem Soc 1941; 63: 3529-3530
20. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
21. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
23. Turkmen S, Oner P, Cinar F et al. Evaluation of leukocyte arylsulfatase-A activity in patients with breast cancer and benign breast disease. Cancer Lett 2001; 166: 95-101
24. Oner P, Bekpinar S, Cinar F, Argun A. Relationship of some endogenous sex steroid hormones to leucocyte arylsulphatase A activities in pre- and post-menopausal healthy women. Horm Metab Res 1994; 26: 301-304
25. Geokas MC, Rinderknecht H. Plasma arylsulfatase and beta-glucuronidase in acute alcoholism. Clin Chim Acta 1973; 46: 27-32
26. Leoni P, Dean RT. Mechanisms of lysosomal enzyme secretion by human monocytes. Biochim Biophys Acta 1983; 762: 378-389
27. Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451
28. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104
29. Miyazaki T, Ise M, Hirata M et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997; 63 [Suppl]: S211-S214